Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!
What Is the Estimated Market Size of the Urticaria Market In 2029?
The quick expansion of the urticaria market in recent years is noteworthy. Forecasted to advance from $4.03 billion in 2024 to $4.77 billion in 2025, it exhibits a compound annual growth rate (CAGR) of 18.2%. The growth observed in the historic period is due to factors such as an increase in allergy incidences, heightened awareness about skin disorders, progressive advancements in immunology and biologics, a rising demand for antihistamines, and enhanced diagnostic methods.
The urticaria market is predicted to undergo speedy expansion in the coming years. The market is forecasted to increase to $9.23 billion by 2029, boasting a compound annual growth rate (CAGR) of 18.0%. This growth in the prophecy period is due to increasing instances of chronic urticaria, enhanced application of biologic treatments, escalated funding in dermatology research, greater access to superior allergy diagnostic methods, and a rise in the creation of personalized medicine. Key trends for the forecast period involve AI-operated diagnostic tools, the creation of new biologics, improvements in personalized immunotherapy, wearable devices for skin monitoring, and the use of telemedicine for allergy management.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23554&type=smp
What Are the Core Market Drivers Propelling Growth in the Urticaria Industry?
The escalation in comprehension and management of skin diseases is forecasted to stimulate the expansion of the urticaria market in the future. The rise in pollution is causing a higher prevalence of skin allergies and conditions, hence increasing the need for awareness and developed treatments. Urticaria facilitates the understanding and treatment of skin diseases by illuminating immune system reactions, promoting research, improving diagnostics, and advancing specialized therapies. For example, The Skin Cancer Foundation, a nonprofit based in the US, stated in February 2024 that 1 in 5 Americans are diagnosed with skin cancer by the age of 70, along with over 2 fatalities every hour within the U.S. This underscores the pressing requirement for preventive approaches, as experiencing five or more sunburns doubles the risk of melanoma. Consequently, the growth in awareness and management of skin diseases is propelling the expansion of the urticaria market.
How Is the Urticaria Market Segmented?
The urticaria market covered in this report is segmented –
1) By Type: Acute Urticaria, Chronic Urticaria
2) By Drug Class: Antihistamines, Anti-inflammation Medications, Antidepressants, Monoclonal Antibodies, Other Drug Classes
3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Acute Urticaria: Allergic Urticaria, Infectious Urticaria, Drug-Induced Urticaria, Contact Urticaria
2) By Chronic Urticaria: Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23554&type=smp
Which Regions Are Driving the Next Phase of the Urticaria Market Growth?
North America was the largest region in the urticaria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in the Urticaria Market Over the Coming Years?
Major organizations in the urticaria market are striving to create innovative solutions like mast cell inhibitor antibodies. These solutions aim to manage chronic spontaneous urticaria by focusing on mast cell activation. Mast cell inhibitor antibody is a specific monoclonal antibody designed to prevent the activation or release of mast cells by blocking specific receptors or signaling pathways. Consequently, this reduces allergic reactions, inflammation, and other disorders mediated by mast cells. For instance, Allakos Inc., a biotechnology firm based in the United States, in May 2024 initiated a Phase 1 clinical trial for AK006, a therapeutic solution for chronic spontaneous urticaria (CSU). This novel therapy targets both IgE-dependent and independent mast cell activation pathways, presenting a potential for wider efficacy in patients who do not respond to antihistamines or previous biologic treatments. By specifically inhibiting mast cell activity via the Siglec-6 receptor, AK006 aims to offer a more comprehensive and long-lasting solution for CSU management. This breakthrough marks an important step forward in urticaria treatment and immunotherapy research.
View the full report here:
https://www.thebusinessresearchcompany.com/report/urticaria-global-market-report
How Is the Urticaria Market Defined and What Are Its Core Parameters?
Urticaria, commonly known as hives, is a skin condition characterized by red, itchy, and raised welts. It occurs due to an allergic reaction, stress, or unknown triggers, leading to histamine release. The condition can be acute (lasting less than six weeks) or chronic (persisting longer). Treatment includes antihistamines, avoiding triggers, and, in severe cases, corticosteroids or immunotherapy.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23554
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model